Company has been created for scientific elaboration and practical application of new biotechnological methods in human disease treatment, originated on applying fetal stem cells and tissues extract. Company in its development reviews elaborating new biotechnological rejuvenating creams on the origin of placental extract, likewise embedding in clinic the anti-aging biotechnological complex.

1. STEM CELLS AND REGENARATIVE
MEDICINE
O.L. Kukharchuk,
V.V. Radchenko,
A.B. Padma Priya,
A.O. Kukharchuk
EmProCell Clinical Research
Pvt. Ltd., Mumbai
SPEAKER:
PROFESSOR
KUKHARCHUK OLEKSANDR
Currently in EmProCell cryobank we have fetal stem cells of the brain, spinal cord, heart,
lungs, liver, kidneys, pancreas and adrenal, muscles and bones, skin and placenta. We are
open for collaboration in the field of Regenerative Medicine.
Contact us: prof@emprocell.com, priya@emprocell.com

2. FETAL PROGENITOR CELLS ARE THE CELLS
DERIVED FROM THE TISSUES OF ABORTUS FETUS
• The following types of
cells can be derived from
abortive material of
different gestation terms
(from 6 to 20 weeks):
• - liver progenitor cells
• - neural progenitor cells
• - gastric and intestinal
progenitor cells
• - lung progenitor cells
• - kidney progenitor cells
• - skin progenitor cells
• - bone tissue progenitor
cells
• - pancreatic progenitor
cells

3. Fetal chondrocytes has high
potential to multiplication,
they can be isolated in
sufficient quantity for
transplantation or for
obtaining specialized fetal
growth factors
Fetal chondrocytes

4. FETAL PROGENITOR CELLS FROM HEART TISSUE
From fetal heart tissue have
been isolated human fetal
cardiomyocytes, cardiac
human fibroblasts,
adventitial fibroblasts,
human microvascular
endothelial
cells, endothelial progenitor
cells, mesenchymal stem
cells, and vascular smooth
muscle cells.
Transplantation of these
cells is effective for
treatment of myocardial
infarct and dilatation
cardiomyopathy.

5. HAEMOPOIETIC PROGENITOR CELLS OF FETAL LIVER WITH
PHENOTYPE CD133+
Progenitor hematopoietic
cells of fetal liver capable
to angio-myogeneic
differentiation, stimulates
blood cells formation and
formation of new vessels,
induces central
immunological tolerance
and enables regeneration
of tissues practically all
damaged organs
Ischemic muscle tissue:
the area of myosymplast
with myoni
Three months after cells
transplantation

6. HEMATOPOIETIC PROGENITOR CELLS OF FETAL LIVER
WITH PHENOTYPE CD133+
Human CD133 fetal liver
progenitor cells promote the
healing of diabetic ischemic
ulcers by paracrine
stimulation of angiogenesis.
Accelerated wound closure
in the presence of
CD133 cells (A, middle) is
associated with higher
temporary wound
capillarization at day 7 (B).
Capillary density declines to
levels of wounds treated with
CD133 cells or collagen gel
alone by day 14 (C)

7. Tissue of fetal kidney consists all
cellular elements in
developmental stages, which has
potential to replace damaged
(injured) renal structures in
adults.
From 12-13 and till 18-20 weeks of
human gestation:
(a–b) localization of SIX2 to the
MM, predominantly to the CM.
(c–d) shaped bodies and renal
stroma.
(e–f) nephrogenic zone and newly
forming tubules.
(g–h) nephrogenic cortex, parietal
epithelium of fetal glomeruli.
(i–j) some differentiated tubules.
FETAL KIDNEY
PROGENITOR CELLS

8. Neural fetal progenitor
cells consists from
precursors of primary
neuroglia, dopaminergic
neurons and
oligodendrocytes, that
lies on the grounds of
therapeutical effects of
the fetal neural cells
transplantation in
neurodegenerative
diseases
FETAL NEURAL
PROGENITOR CELLS

9. FETAL PANCREATIC PROGENITOR CELLS
Fetal pancreas consist
cells – precursors of
Langerhans islets cells,
that could be the basis for
treatment in diabetes
mellitus 1 type

10. FETAL PROGENITOR CELLS TRANSPLANTATION
 Bright example of fetal
progenitor cells induced
reparative regeneration is
polytrauma.
 In these conditions, likewise
after any complicated
operation, body of patient
mobilizes all stem cells
resources to restore the
function of the damaged
organs and tissues.
 If stem resources is
insufficient then the patient
dies.
 Regenerative medicine
contributes chance of
survival in such type of
patients.

11. FETAL PROGENITOR CELLS IN BURNS III-A STAGE
TREATMENT
Currently in EmProCell cryobank we have fetal stem cells of the brain, spinal cord, heart, lungs, liver,
kidneys, pancreas and adrenal, muscles and bones, skin and placenta. We are open for collaboration
in the field of Regenerative Medicine. Contact us: prof@emprocell.com, priya@emprocell.com

12. TRANSPLANTATION OF FETAL PROGENITOR CELLS IN
POSTOPERATIVE PERIOD TO PANCREONECROSIS PATIENTS
Sewing of umbilical cord Ready implant
Insertion of implant on the zone of pancreatic necrosis
De-freezing umbilical cord
Currently in EmProCell cryobank we have fetal stem cells of the brain, spinal cord, heart, lungs, liver,
kidneys, pancreas and adrenal, muscles and bones, skin and placenta. We are open for collaboration
in the field of Regenerative Medicine. Contact us: prof@emprocell.com, priya@emprocell.com

13. TRANSPLANTATION OF FETAL PROGENITOR CELLS IN
POSTOPERATIVE PERIOD TO PANCREONECROSIS
PATIENTS
Removal of cord tissue implant following 3 days after operation
Currently in EmProCell cryobank we have fetal stem cells of the brain, spinal cord, heart, lungs, liver,
kidneys, pancreas and adrenal, muscles and bones, skin and placenta. We are open for collaboration
in the field of Regenerative Medicine. Contact us: prof@emprocell.com, priya@emprocell.com

14. TRANSPLANTATION OF FETAL PROGENITOR CELLS IN
POSTOPERATIVE PERIOD TO PANCREONECROSIS
PATIENTS
Fetal progenitor cells
Introduction of fetal progenitor
cells stem cells in the subclavian
vein
Currently in EmProCell cryobank we have fetal stem cells of the brain, spinal cord, heart, lungs,
liver, kidneys, pancreas and adrenal, muscles and bones, skin and placenta. We are open for
collaboration in the field of Regenerative Medicine. Contact us:
prof@emprocell.com, priya@emprocell.com
Mortality rate reduced to 9 times.
In course of 3 years after treatment
formation of cysts in pancreas were
not observed

15. CHRONIC LEGS ISCHEMIA
In clinic 65 patients
were examined with
chronic legs ischemia.
Age of patients: from
55 to 78 years.
Patients had last stage
of disease (alternative
treatment – leg
amputation)

16. CHRONIC LEGS ISCHEMIA • Type of cells
suspension:
hematopoietic cells of
fetal liver.
• Gestation term: 12
weeks.
• Dose: 35,0 x 10^6/ml.
• Phenotype: CD34^+
CD133^+ CD38^-
CD45RA^low
CD71^low CD7HLA-
DR^low.
• Amount of
transplantation: 1
• Follow-up period: 16
months

17. CHRONIC LEGS ISCHEMIA
 Surgical treatment: local
injection of Fetal
progenitor cells along the
sclerotic arteries

18. CHRONIC LEGS ISCHEMIA: CASE REPORT
BEFORE CELL
TRANSPLANTATION
AFTER CELL
TRANSPLANTATION

19. CHRONIC LEGS ISCHEMIA: CASE REPORT
BEFORE CELL
TRANSPLANTATION
AFTER CELL
TRANSPLANTATION

20. Level of microcirculation (unit)
 Before treatment - 4.28 ±0.34
 1 month after EPC–transplantation - 5.24±0.27 (р<0.05)
 3 month after EPC–transplantation - 6.32±0.41 (р<0.05)
 6 month after EPC–transplantation - 7.57±0.62 (р<0.01)
Reserve of capillarity blood stream (%)
 Before treatment - 89.32±12.5
 1 month after EPC–transplantation - 112.34±10.9 (р<0.01)
 3 month after EPC–transplantation - 137.83±9.2 (р<0.05)
 6 month after EPC–transplantation - 150.31±10.5 (р<0.05)
Dilatation of precapillary sphincters
 Before treatment - ( - )
 1 month after EPC–transplantation - ( + )
 3 month after EPC–transplantation - ( + )
 6 month after EPC–transplantation - ( + )
Distance of painless walk
 Before treatment – 50 m
 1 month after EPC–transplantation - 300 m
 3 month after EPC–transplantation - 450 m
 6 month after EPC–transplantation - 500-1500 m
RESULTS OF ENTIRE CELL-TREATMENT GROUP

21. PATIENTS ESTIMATION ON EFFICACY OF
FETAL PROGENITOR CELLS
TRANSPLANTATION AT THE END OF
IVESTIGATION:
“SIGNIFICANT IMPROVEMENT” – 90%
“IMPROVEMENT” – 10%
“NON SIGNIFICANT IMPROVEMENT” – 0%
“WITHOUT CHANGE” – 0%

22. LIVER CIRRHOTIC PATIENTS
In clinic 43 patients were
examined with alcoholic liver
cirrhosis:
• Age of patients: from 35 to 55
years.
• Disease span - 7,10±0,25 years.
• Patients had last stage of disease
with higher level of liver injury
(alternative treatment – liver
transplantation)

23. LIVER CIRRHOTIC PATIENTS
• Type of cells
suspension:
hematopoietic cells and
hepatoblasts of fetal
liver
• Gestation term: 6-8
weeks
• Dose: 15,0 x 10^6/ml.
• Phenotype: CD34^+
CD45RA^low CD71^low
CD7HLA-DR^low
Albumine^+
• Amount of
transplantation: 1
• Follow-up period: 14
months

24. LIVER CIRRHOTIC PATIENTS
FPC-
transplantation

25. LIVER CIRRHOTIC PATIENTS
FPC-
transplantation

26. PATIENTS ESTIMATION ON EFFICACY OF FETAL
PROGENITOR CELLS RANSPLANTATION AT THE END OF
INVESTIGATION:
“SIGNIFICANT IMPROVEMENT” – 95%
“IMPROVEMENT” – 5%
“NON SIGNIFICANT IMPROVEMENT” – 0%
“WITHOUT CHANGE” – 0%

27. DIABETES MELLITUS TYPE 2
• FPC-transplantation
significantly decrease
blood levels of glucose
and Hb-Glu in
patients with type 2 of
diabetes mellitus
FPC-
transplantation

28. DIABETES MELLITUS TYPE 2
 FPC-transplantation
significantly decrease
blood levels of insulin and
C-peptide
FPC-
transplantation

29. SEXUAL DYSFUNCTION
• Treatment: intravenous and
subcutaneous human FPC
administration.
• Type of human cells
suspension: hematopoietic
cells of fetal liver and
progenitor cell, all type.
• Gestation term: 6-7 weeks.
• Dose: 55,0 x 10^6/ml.
• Phenotype: CD34^+ CD133^+
CD38^- CD45RA^low
CD71^low CD7HLA-DR^low.
• Amount of transplantation: 1
• Follow-up period: 26 months

30. CHARACTERISTICS OF SEXUAL FUNCTION BEFORE
FETAL PROGENITOR CELLS TRANSPLANTATION
 Before start of tests
2 of 4 men have
imperfect sexual
function.
2 of them has
climax. Two patient
has subnormal
libido, its absence –
two other patient.
 All 6 women has
climax with
absence of libido
PatientPatient sexsex ageage ObservatiObservati
on timeon time
((monthsmonths))
SexualSexual
functionfunction
LibidoLibido
G1G1 manman 5858 1414 NotNot
infringedinfringed
SubnormalSubnormal
G2G2 manman 6565 1212 ClimaxClimax AbsentAbsent
G3G3 manman 6161 1818 NotNot
infringedinfringed
SubnormalSubnormal
G4G4 manman 6363 1515 ClimaxClimax AbsentAbsent
G5G5 womanwoman 5959 1818 ClimaxClimax SubnormalSubnormal
G6G6 womanwoman 6060 1414 ClimaxClimax AbsentAbsent
G7G7 womanwoman 5858 1212 ClimaxClimax AbsentAbsent
G8G8 womanwoman 6868 1616 ClimaxClimax AbsentAbsent
G9G9 womanwoman 6767 1616 ClimaxClimax AbsentAbsent
G10G10 womanwoman 6565 1717 ClimaxClimax AbsentAbsent

31. CHARACTERISTICS OF SEXUAL FUNCTION AFTER
FETAL PROGENITOR CELLS TRANSPLANTATION
 Six months after
transplantation the
potency of all men
was restored on a
back of sharp rise of
libido.
 3 women have
restored menstrual
cycle. Appearance of
libido – all of them.
PatientPatient sexsex ageage ObservationObservation
timetime
((monthsmonths))
Sexual functionSexual function LibidoLibido
G1G1 manman 5858 1414 Not infringedNot infringed ElevationElevation
G2G2 manman 6565 1212 Potency isPotency is
renewedrenewed
ElevationElevation
G3G3 manman 6161 1818 Not infringedNot infringed ElevationElevation
G4G4 manman 6363 1515 Potency isPotency is
renewedrenewed
ElevationElevation
G5G5 womanwoman 5959 1818 Appearance ofAppearance of
menstrual fluxmenstrual flux
ElevationElevation
G6G6 womanwoman 6060 1414 WithoutWithout
changeschanges
AppearanceAppearance
G7G7 womanwoman 5858 1212 Appearance ofAppearance of
menstrual fluxmenstrual flux
AppearanceAppearance
G8G8 womanwoman 6868 1616 Appearance ofAppearance of
menstrual fluxmenstrual flux
AppearanceAppearance
G9G9 womanwoman 6767 1616 WithoutWithout
changeschanges
AppearanceAppearance
G10G10 womanwoman 6565 1717 WithoutWithout
changeschanges
AppearanceAppearance

32. THE CLINICAL EFFECTIVENESS OF THE FPC-
TRANSPLANTATION AT DIFFERENT FORMS OF
MALE INFERTILITY
 We performed complex investigation of 29 infertile men;
with secretory infertility – 19 patients; with excretory – 10
patients. The program of investigation included sperm's
analysis and explanation of the sex hormones level in
blood.
 The control investigation were conducted over 3 month
after the FPC-transplantation.

33. THE CLINICAL EFFECTIVENESS OF THE
FPC-TRANSPLANTATION IN SECRETORY
FORM OF MALE INFERTILITY
Sperms volume, ml
 Before transplantation (n=19) - 3,73±0,50
 After transplantation (n=19) - 3,93±0,38
Concentration of spermatozoids (bill/ml)
 Before transplantation (n=19) - 4,81±0,96
 After transplantation (n=19) - 11,32±1,43
Amount of spermatozoids (bill)
 Before transplantation (n=19) - 14,89±0,82

After transplantation (n=19) - 43,89±4,82

34. THE CLINICAL EFFECTIVENESS OF THE
FPC-TRANSPLANTATION IN EXCRETORY
FORM OF MALE INFERTILITY
Sperms volume, ml
 Before transplantation
(n=10) - 3,86±0,17
 After transplantation
(n=10) - 4,30±0,11
Concentration of
spermatozoids (bill/ml)
 Before transplantation
(n=10) - 49,75±4,03
 After transplantation
(n=10) - 53,62±5,26
Amount of spermatozoids
(bill)
 Before transplantation
(n=10) - 141,00±8,40
 After transplantation
(n=10) - 227,20±17,1
Motility of spermatozoids
“a” (%)
 Before transplantation
(n=10) - 6,60±044
 After transplantation
(n=10) - 13,25±1,08
Motility of spermatozoids
“b” (%)
 Before transplantation
(n=10) - 11,67±1,03
 After transplantation
(n=10) - 16,75±1,19
Motility of spermatozoids
“a + b” (%)
 Before transplantation
(n=10) - 17,17±1,42
 After transplantation
(n=10) - 30,00±1,75

35. CONCLUSIONS
• We established the statistically true increasing
of concentration and quantity of spermatozoids
in secretory infertility (67%); and statistically
true increasing of motility of spermatozoids in
excretory infertility men (70%).
• After transplantation 40% treatments men had
positive reproductive result.

36. THANKS FOR YOUR ATTENTION !
More detailed information about the clinical application
of fetal progenitor cells mentioned in the information
brochure